Results 161 to 170 of about 394,130 (296)

Cancer pain: current practice and emerging targets

British Journal of Pharmacology, EarlyView.
Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye, Marcin Chwistek, Zhiting Gong, Vanessa Uzonwanne, Xiaojie Shi, Arpad Szallasi   +5 more
wiley   +1 more source

Danthron as a novel IL-6R agonist promotes thrombopoiesis via the SRC/RAS/MAPK pathway. [PDF]

Front Immunol
Liao R, Luo J, Li X, Tang X, Huang M, Zhou L, Yun L, Liu Z, Jiang P, Wang X, Gan X, Wang L, Wu J.   +12 more
europepmc   +1 more source

Cardiotoxicity of BRAF/MEK inhibitors

British Journal of Pharmacology, EarlyView.
Abstract Rapidly accelerated fibrosarcoma type B/B‐Raf proto‐oncogene, serine/threonine kinase (BRAF) and mitogen‐activated protein kinase (MEK) inhibitors have transformed outcomes in cancer therapy, particularly in melanoma. However, cardiovascular toxicities are increasingly recognized in real‐world clinical practice.
Katharina Seuthe, Valerie Lohner, Kevin Terre, Thomas Riffelmacher, Roman Pfister   +4 more
wiley   +1 more source

Cancer risk in adults with pathogenic germline variants in RAS/MAPK genes using genomic ascertainment. [PDF]

Genet Med
Kim J, Ney G, Frone MN, Haley JS, Ramos MLF, Mirshahi UL, Astiazaran-Symonds E, Shandrina M, Urban G, Rao HS, Stahl RC, Golden A, Yohe ME, Gross AM, Ding Y, Carey DJ, Gelb BD, Stewart DR.   +17 more
europepmc   +1 more source

Targeting KRAS for cancer therapy

British Journal of Pharmacology, EarlyView.
In recent years, therapeutics targeted against KRAS proto‐oncogene GTPase (KRAS)‐mutant cancers have seen significant progress. Herein we outline the biology and epidemiology of KRAS alterations at the lineage and allele levels, reviewing the clinical evidence for KRASG12C inhibition from the discovery of the recessive switch pocket to sotorasib ...
Jianlong Jia, Ruonan Liu, Tonia A. Adamide, Isis E. Fernandez, Georgios T. Stathopoulos   +4 more
wiley   +1 more source

Downregulation of KRTAP2‐3 Suppresses Proliferation and Tumor Formation of Oral Cancer Cells via Inactivation of KRAS Signals

Cancer Science, EarlyView.
KRTAP2‐3 drives OSCC progression by sustaining both mesenchymal and proliferative properties through KRAS signaling. Loss of KRTAP2‐3 induces MET, suppresses KRAS pathway activation, and markedly reduces tumor cell proiferation and tumor formation as illustarted in Figure.
Qianqian Miao, Zhijun Huang, Kazuki Takahashi, Haruka Ibi, Kohei Miyazono, Katarzyna A. Podyma‐Inoue, Tetsuro Watabe   +6 more
wiley   +1 more source

Loss of LLGL1 Elevates EGFR/RAS/MAPK Signaling and Remodels EMT Markers in Huh-7 Hepatocellular Carcinoma Cells. [PDF]

Int J Mol Sci
Yıldız G, Karabulut S, Dincer T, Toraman B.   +3 more
europepmc   +1 more source

Cognitive Dysfunctions in Intellectual Disabilities: The Contributions of the Ras-MAPK and PI3K-AKT-mTOR Pathways.

Annual review of genomics and human genetics (Print), 2017
S. Borrie, H. Brems, E. Legius, C. Bagni
semanticscholar   +1 more source

Combined MEK1/2 and Autophagy Inhibition Suppresses Tumor Growth via STING‐Mediated Type I Interferon Response in iCCA

Cancer Science, EarlyView.
Through bioinformatic analyses, iCCA cell models, and in vivo xenograft experiments, we show that autophagy inhibition sensitizes iCCA to MEK1/2 blockade by enhancing STING‐dependent type I interferon signaling. These findings support combined MEK1/2 and autophagy inhibition as a promising therapeutic strategy for iCCA. ABSTRACT The RAF–MEK–ERK pathway
Chengqiang Sun, Zheng Gao, Enfu Dong, Liangxia Ding, Shanru Feng, Jiafeng Chen, Pascal Kwangwari, Yinghong Shi, Weiren Liu, Xin Zhang, Ao Huang, Jian Zhou, Sheng Wang, Jia Fan, Xiutao Fu, ZhenBin Ding   +15 more
wiley   +1 more source

Impact of RAS-MAPK Pathway Genetic Alterations on Radiotherapy Response in Metastatic Lung Adenocarcinoma. [PDF]

JCO Precis Oncol
Cederquist GY, Anderson ES, Lis E, Boe L, Newman WC, Barzilai O, Bilsky M, Yamada Y, Higginson DS, Schmitt AM.   +9 more
europepmc   +1 more source